Physician profile
Scott Bilyeu
NPI 1053516971
$3,582.49
in general payments reported to CMS, 2019-2025
35 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $572 · 2021: $883 · 2022: $59.43 · 2023: $498 · 2024: $487 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,003.45 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $272.48 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $236.78 | 2019-2021 | |
| Pfizer INC. | $186.37 | 2019-2025 | |
| Lilly USA, LLC | $184.59 | 2019-2021 | |
| Novo Nordisk INC | $179.24 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $176.25 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.87 | 2019-2023 | |
| Mylan Specialty L.P. | $133.60 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $133.48 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $99.86 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.36 | 2023-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $86.32 | 2021-2024 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $75.72 | 2019-2024 | Austedo Xr, Ajovy |
| Abbott Laboratories | $74.82 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $61.57 | 2023-2024 | Rexulti |
| Corcept Therapeutics | $54.38 | 2020 | |
| Amarin Pharma, INC. | $45.45 | 2021-2022 | |
| Abbvie INC. | $45.25 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.43 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $32.17 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $27.37 | 2021 | |
| Sumitomo Pharma America, INC. | $22.72 | 2024 | Gemtesa |
| Viatris Specialty LLC | $21.63 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $20.19 | 2021 | |
| Organogenesis INC. | $17.55 | 2023 | Puraply |
| Dexcom, INC. | $16.76 | 2023 | Dexcom G6 Transmitter |
| Nalpropion Pharmaceuticals LLC | $14.64 | 2019 | |
| Currax Pharmaceuticals LLC | $14.61 | 2023 | Nexletol, Contrave, Nexlizet |
| Antares Pharma, INC. | $14.12 | 2021 | |
| Astellas Pharma US INC | $13.25 | 2024 | Veozah |
| Allergan, INC. | $13.10 | 2019 | |
| Electromed, INC. | $12.83 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.66 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Bilyeu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.